We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dried Blood Used to Screen Newborns for Severe Immunodeficiency

By LabMedica International staff writers
Posted on 25 Aug 2010
A molecular test on dried blood spots is very sensitive for diagnosing severe combined immunodeficiency (SCID) in newborns.

The assay employs a quantitative polymerase chain reaction (PCR) for T-cell receptor excision circles (TREC), which are copies of DNA produced only by T-cells. More...
If the calculated TREC count is less than 30 copies/μL, it is associated with 100% sensitivity and 97% specificity for identifying SCID.

Severe combined immunodeficiency (SCID) represents a group of rare, sometimes fatal, congenital disorders characterized by little or no immune response. The defining feature of SCID, commonly known as "bubble boy" disease, is a defect in the specialized white blood cells (B- and T-lymphocytes). A review of the various methods used to diagnose SCID was published in the May 2010 issue of Pediatrics.

The review noted that a second blood spot study evaluated a two-tiered approach in which interleukin IL-7 was measured first using an enzyme-linked immunosorbent assay (ELISA), and then TRECs from those with elevated IL-7 levels, which occurs in the absence of T-cells. This study included samples from 13 children with SCID and 183 anonymized dried blood spots. For the first tier (IL-7 measurement) they calculated 96.1% specificity and 85% sensitivity (confidence interval: 55%–98%); for the second tier (TREC count) they calculated a specificity of 92.3% and a sensitivity that "approaches 100%.” If the more stringent standard of undetectable TRECs is used as a positive test result, they calculated a false-positive rate of 1.5% among children discharged from routine nurseries and 5% among children from special-care nurseries.

The study reported that on whole blood samples from infants with a median age of four months, lymphocyte counts that were less than 2.8 x 109/L had a sensitivity of 86% and a specificity of 94% for detecting SCID. From another study, they determined that among infants with a median age of 84 days, lymphocyte counts that were less than 5,000/μL had a sensitivity of only 56%, but a specificity of 100%, for detecting SCID.

Ellen A. Lipstein, M.D., M.P.H. of the MassGeneral Hospital for Children, (Boston, MA, USA), said, "The development of methods to screen for SCID by using dried blood spots, in contrast to using lymphocyte counts, which require whole blood, improves the feasibility of instituting SCID screening within current programs."

Related Links:
MassGeneral Hospital for Children




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Automated Immunoassay Analyzer
SuperFlex™
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.